URMC Research Network

Find People
Last Name
More Search Options

Jainulabdeen J. Ifthikharuddin

TitleAssociate Professor of Clinical
InstitutionSchool of Medicine and Dentistry
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
 Awards And Honors
2004     Best Teacher Award  | Hematology/Oncology Fellowship Program
1997     Strong Memorial Hospital Innovative Improvement Program  | Strong Memorial Hospital
      Ad hoc manuscript reviewer  | Journal - Thrombosis Research
      Ad hoc manuscript reviewer  | Journal - Blood Cells, Molecules and Diseases
1999     AMGEN Fellowship Grant  | AMGEN
Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematology (MRC Path). He subsequently completed residency training in Internal Medicine and fellowship in Hematology/Oncology at The University of Rochester and joined the faculty in the year 2000. He is board certified in Hematology. In addition to clinical and teaching responsibilities, he is an active participant in several clinical trials.

 Selected Publications
List All   |   Timeline
  1. Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7.
    View in: PubMed
  2. Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug; 29(7):439-50.
    View in: PubMed
  3. Milner LA, Becker MW, Bernstein SH, Bruckner L, Friedberg JW, Holland GA, Ifthikharuddin JJ, Liesveld JL, Mathes EJ, Menchel HL, Mullen CA, Sasson T, Phillips GL. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
    View in: PubMed
  4. Phillips GL, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
    View in: PubMed
  5. Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
    View in: PubMed
  6. Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, Abboud CN, Sanz I, Huggins J. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006 Apr 1; 107(7):2895-903.
    View in: PubMed
  7. Dib EG, Ifthikharuddin JJ, Scott GA, Partilo SR. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res. 2005 Feb; 29(2):233-4.
    View in: PubMed
  8. Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. Semin Oncol. 2004 Dec; 31(6 Suppl 18):59-61.
    View in: PubMed
  9. Komrokji R, Ifthikharuddin JJ, Felgar RE, Abboud CN, Wedow LA, Connaughton A, Bennett JM. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review. Am J Hematol. 2004 Aug; 76(4):389-94.
    View in: PubMed
  10. Fu SQ, Abboud CN, Brennan JK, Ifthikharuddin JJ, Nichols D, Liesveld JL. Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation. Blood Cells Mol Dis. 2002 May-Jun; 28(3):315-21.
    View in: PubMed
  11. Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transplant. 2002; 8(12):662-5.
    View in: PubMed
  12. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol. 2000 Oct; 65(2):171-3.
    View in: PubMed
  13. Ifthikharuddin JJ, Janas J, Phatak PD. Isolated splenic blastic transformation of idiopathic myelofibrosis and response to splenectomy. Leuk Res. 1997 Mar; 21(3):255-7.
    View in: PubMed
  14. Lim SH, Ifthikharuddin JJ. Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders. Leuk Lymphoma. 1994 Sep; 15(1-2):61-4.
    View in: PubMed


Ifthikharuddin's Networks

Similar People
Same Department